Literature DB >> 26586005

In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease".

Shigeo Horie1, Satoru Muto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26586005     DOI： 10.1007/s10157-015-1154-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  4 in total

1.  The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Authors:  Satoru Muto; Haruna Kawano; Eiji Higashihara; Ichiei Narita; Yoshifumi Ubara; Takayuki Matsuzaki; John Ouyang; Vicente E Torres; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2015-02-07       Impact factor: 2.801

2.  Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.

Authors:  Masaru Horio; Enyu Imai; Yoshinari Yasuda; Tsuyoshi Watanabe; Seiichi Matsuo
Journal:  Am J Kidney Dis       Date:  2010-04-22       Impact factor: 8.860

3.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

4.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.